Sirolimus: a single center experience in combination with calcineurin inhibitors
| Autor: | Kathy Nicholls, Murray J. Leikis, Rowan G. Walker, Vlado Perkovic, Rosemary Masterson |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Graft Rejection
medicine.medical_specialty Time Factors medicine.medical_treatment Calcineurin Inhibitors Single Center Gastroenterology Postoperative Complications Adrenal Cortex Hormones Internal medicine medicine Humans Kidney transplantation Survival analysis Sirolimus Transplantation business.industry Graft Survival Immunosuppression Ciclosporin medicine.disease Kidney Transplantation Survival Analysis Surgery Calcineurin Treatment Outcome Drug Therapy Combination business Immunosuppressive Agents Follow-Up Studies medicine.drug |
| Zdroj: | Transplantation Proceedings. 35:S99-S104 |
| ISSN: | 0041-1345 |
| DOI: | 10.1016/s0041-1345(03)00219-7 |
| Popis: | A retrospective survey was performed to establish patient and graft outcome for all 41 patients at our centre receiving sirolimus (SRL) in combination with calcineurin inhibition (CNI) as primary therapy for the 6 years prior to March 2002. Patient mortality [12%; n = 5 (TTP, lymphoma, mucormycosis, and small bowel perforation] was significantly higher at 3 months compared with those not receiving SRL, but not thereafter. 12.8% had delayed graft function and 33% had one or more episodes of rejection in the first 6 months. Mean GFR at 12 months was significantly lower (47.3 mL/min) in the SRL group compared with those not receiving SRL (51.3 mL/min). Twenty-two patients had a 12-month protocol biopsy; CNI toxicity was present in 36%. SRL was associated with significant hyperlipidaemia (serum cholesterol, 5.2 +/- 1.4 at baseline vs 7.3 +/- 1.7 mmol/L at 3 months, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect